FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2920598411> ?p ?o ?g. }

• W2920598411 endingPage "1354" @default.
• W2920598411 startingPage "1347" @default.
• W2920598411 abstract "Although bortezomib and rituximab have synergistic activity in patients with lymphoma and both can attenuate graft-versus-host disease (GVHD), the drugs have not been used together in patients undergoing allogeneic stem cell transplantation (alloSCT). In this phase I/II trial, we assessed the safety and activity of bortezomib added to the rituximab (R) plus BEAM (carmustine, etoposide, cytarabine, melphalan) regimen in patients with relapsed lymphoma undergoing alloSCT. Primary GVHD prophylaxis consisted of tacrolimus and methotrexate. Bortezomib (1 to 1.3 mg/m2 per dose) was administered i.v. on days –13, –6, –1, and +2. We performed inverse probability weighting analysis to compare GVHD and survival results with an historical control group that received R-BEAM without bortezomib. Thirty-nine patients were assessable for toxic effects and response. The median age was 54 years. The most common diagnosis was diffuse large B cell lymphoma (41%). Twenty-two patients (56%) and 17 patients (44%) received their transplants from matched related and matched unrelated donors, respectively. The maximum tolerated bortezomib dose was 1 mg/m2. The weighted cumulative incidences of grades II to IV and III or IV acute GVHD were 50% and 34%, respectively; these incidences and survival rates were not significantly different from those of the control group. Median survival was not reached in patients age ≤ 50 years and with a long follow-up time of 60.7 months. The R-BEAM regimen has a survival benefit in lymphoma patients age ≤ 50 years undergoing alloSCT. The addition of bortezomib has no impact on survival or incidence of GVHD." @default.
• W2920598411 created "2019-03-11" @default.
• W2920598411 creator A5013543100 @default.
• W2920598411 creator A5016928938 @default.
• W2920598411 creator A5029855695 @default.
• W2920598411 creator A5033737136 @default.
• W2920598411 creator A5035321251 @default.
• W2920598411 creator A5039986529 @default.
• W2920598411 creator A5047806967 @default.
• W2920598411 creator A5048913229 @default.
• W2920598411 creator A5049385583 @default.
• W2920598411 creator A5055885925 @default.
• W2920598411 creator A5066894053 @default.
• W2920598411 creator A5067252491 @default.
• W2920598411 creator A5068834306 @default.
• W2920598411 creator A5069676375 @default.
• W2920598411 creator A5080068726 @default.
• W2920598411 creator A5083279961 @default.
• W2920598411 creator A5085076031 @default.
• W2920598411 creator A5091083304 @default.
• W2920598411 date "2019-07-01" @default.
• W2920598411 modified "2023-09-23" @default.
• W2920598411 title "Allogeneic Transplantation after Myeloablative Rituximab/BEAM ± Bortezomib for Patients with Relapsed/Refractory Lymphoid Malignancies: 5-Year Follow-Up Results" @default.
• W2920598411 cites W1491993932 @default.
• W2920598411 cites W1530764705 @default.
• W2920598411 cites W1799226444 @default.
• W2920598411 cites W1841628176 @default.
• W2920598411 cites W1883328448 @default.
• W2920598411 cites W1966136277 @default.
• W2920598411 cites W1978345721 @default.
• W2920598411 cites W1985343909 @default.
• W2920598411 cites W1995090169 @default.
• W2920598411 cites W2006493080 @default.
• W2920598411 cites W2009187570 @default.
• W2920598411 cites W2038880599 @default.
• W2920598411 cites W2038981426 @default.
• W2920598411 cites W2041355950 @default.
• W2920598411 cites W2058887761 @default.
• W2920598411 cites W2070241795 @default.
• W2920598411 cites W2072549718 @default.
• W2920598411 cites W2075816749 @default.
• W2920598411 cites W2078346968 @default.
• W2920598411 cites W2082480900 @default.
• W2920598411 cites W2087613277 @default.
• W2920598411 cites W2096617375 @default.
• W2920598411 cites W2097470232 @default.
• W2920598411 cites W2103255742 @default.
• W2920598411 cites W2110395869 @default.
• W2920598411 cites W2112632101 @default.
• W2920598411 cites W2123992350 @default.
• W2920598411 cites W2132589242 @default.
• W2920598411 cites W2133201432 @default.
• W2920598411 cites W2142099365 @default.
• W2920598411 cites W2144789671 @default.
• W2920598411 cites W2164825132 @default.
• W2920598411 cites W2333259690 @default.
• W2920598411 cites W2337724293 @default.
• W2920598411 cites W2379365975 @default.
• W2920598411 cites W2590030902 @default.
• W2920598411 cites W2618073389 @default.
• W2920598411 cites W2769990542 @default.
• W2920598411 cites W2770775068 @default.
• W2920598411 cites W2782992298 @default.
• W2920598411 cites W2789742309 @default.
• W2920598411 cites W4293241248 @default.
• W2920598411 doi "https://doi.org/10.1016/j.bbmt.2019.02.022" @default.
• W2920598411 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6615973" @default.
• W2920598411 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30826465" @default.
• W2920598411 hasPublicationYear "2019" @default.
• W2920598411 type Work @default.
• W2920598411 sameAs 2920598411 @default.
• W2920598411 citedByCount "3" @default.
• W2920598411 countsByYear W29205984112019 @default.
• W2920598411 countsByYear W29205984112022 @default.
• W2920598411 crossrefType "journal-article" @default.
• W2920598411 hasAuthorship W2920598411A5013543100 @default.
• W2920598411 hasAuthorship W2920598411A5016928938 @default.
• W2920598411 hasAuthorship W2920598411A5029855695 @default.
• W2920598411 hasAuthorship W2920598411A5033737136 @default.
• W2920598411 hasAuthorship W2920598411A5035321251 @default.
• W2920598411 hasAuthorship W2920598411A5039986529 @default.
• W2920598411 hasAuthorship W2920598411A5047806967 @default.
• W2920598411 hasAuthorship W2920598411A5048913229 @default.
• W2920598411 hasAuthorship W2920598411A5049385583 @default.
• W2920598411 hasAuthorship W2920598411A5055885925 @default.
• W2920598411 hasAuthorship W2920598411A5066894053 @default.
• W2920598411 hasAuthorship W2920598411A5067252491 @default.
• W2920598411 hasAuthorship W2920598411A5068834306 @default.
• W2920598411 hasAuthorship W2920598411A5069676375 @default.
• W2920598411 hasAuthorship W2920598411A5080068726 @default.
• W2920598411 hasAuthorship W2920598411A5083279961 @default.
• W2920598411 hasAuthorship W2920598411A5085076031 @default.
• W2920598411 hasAuthorship W2920598411A5091083304 @default.
• W2920598411 hasBestOaLocation W29205984111 @default.
• W2920598411 hasConcept C126322002 @default.
• W2920598411 hasConcept C141071460 @default.
• W2920598411 hasConcept C143998085 @default.
• W2920598411 hasConcept C2776364478 @default.

• next